Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430202 · ClinicalTrials.gov registry record · Phase 1
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Not yet
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT07430202 is a Phase 1 study that has not yet begun recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 27 participants.
The verdict
NCT07430202, a Phase 1 study, has not yet begun recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG DRP-104
- DRUG DNAJB1-PRKACA Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07430202
The ClinicalTrials.gov registry entry for NCT07430202 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT07430202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07430202 about?
NCT07430202 is a clinical study titled "A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)". The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, a...
What is the current status of trial NCT07430202?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07430202?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), DRP-104 (DRUG), DNAJB1-PRKACA Peptide Vaccine (DRUG).
Who is sponsoring clinical trial NCT07430202?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.